180
Views
4
CrossRef citations to date
0
Altmetric
Review

Waldenström’s Macroglobulinemia: An Exploration into the Pathology and Diagnosis of a Complex B-Cell Malignancy

, & ORCID Icon
Pages 795-807 | Published online: 30 Aug 2021

References

  • Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of waldenstrom’s macroglobulinemia: consensus panel recommendations from the second international workshop on waldenstrom’s macroglobulinemia. Semin Oncol. 2003;30(2):110–115. doi:10.1053/sonc.2003.50082
  • Swerdlow S, Campo E, Pileri S, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390. doi:10.1182/blood-2016-01-643569
  • Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117(19):5019–5032. doi:10.1182/blood-2011-01-293050
  • Hunter Z, Xu L, Zhou Y, et al. Whole-genome sequencing results from 30 patients with waldenstrom’s macroglobulinemia. Blood. 2011;118(21):434. doi:10.1182/blood.V118.21.434.434
  • Lynch RC, Gratzinger D, Advani RH. Clinical impact of the 2016 update to the WHO lymphoma classification. Curr Treat Options Oncol. 2017;18(7):45. doi:10.1007/s11864-017-0483-z
  • Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström’s macroglobulinemia. N Engl J Med. 2012;367(9):826–833. doi:10.1056/NEJMoa1200710
  • Treon SP, Cao Y, Xu L, Yang G, Liu X, Hunter ZR. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood. 2014;123(18):2791–2796. doi:10.1182/blood-2014-01-550905
  • Hunter ZR, Xu L, Yang G, et al. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood. 2014;123(11):1637–1646. doi:10.1182/blood-2013-09-525808
  • Pophali PA, Bartley A, Kapoor P, et al. Prevalence and survival of smouldering Waldenström macroglobulinaemia in the United States. Br J Haematol. 2019;184(6):1014–1017. doi:10.1111/bjh.15201
  • García-Sanz R, Montoto S, Torrequebrada A, et al. Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol. 2001;115(3):575–582. doi:10.1046/j.1365-2141.2001.03144.x
  • Kristinsson SY, Koshiol J, Goldin LR, et al. Genetics- and immune-related factors in the pathogenesis of lymphoplasmacytic lymphoma/ Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma. 2009;9(1):23–26. doi:10.3816/CLM.2009.n.004
  • Treon SP, Tripsas C, Hanzis C, et al. Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2012;12(6):433–437. doi:10.1016/j.clml.2012.08.006
  • Giordano TP, Henderson L, Landgren O, et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA. 2007;297(18):2010–2017. doi:10.1001/jama.297.18.2010
  • Mailankody S, Landgren O. Monoclonal gammopathy of undetermined significance and Waldenström’s macroglobulinemia. Best Pract Res Clin Haematol. 2016;29(2):187–193. doi:10.1016/j.beha.2016.08.015
  • Kyle RA, Larson DR, Therneau TM, et al. Long-term follow-up of monoclonal gammopathy of undetermined significance. N Engl J Med. 2018;378(3):241–249. doi:10.1056/NEJMoa1709974
  • Swerdlow SH, Kuzu I, Dogan A, et al. The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing. Virchows Arch. 2016;468(3):259–275. doi:10.1007/s00428-015-1858-9
  • Sabattini E, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010;102(3):83–87.
  • Dimopoulos MA, Kastritis E. How I treat Waldenström macroglobulinemia. Blood. 2019;134(23):2022–2035. doi:10.1182/blood.2019000725
  • Ciccarelli BT, Patterson CJ, Hunter ZR, et al. Hepcidin is produced by lymphoplasmacytic cells and is associated with anemia in Waldenström’s macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011;11(1):160–163. doi:10.3816/CLML.2011.n.038
  • Samba-Mondonga M, Calvé A, Mallette FA, Santos MM. MyD88 regulates the expression of SMAD4 and the iron regulatory hormone hepcidin. Front Cell Dev Biol. 2018;6:105. doi:10.3389/fcell.2018.00105
  • Castillo JJ, Garcia‐Sanz R, Hatjiharissi E. Recommendations for the diagnosis and initial evaluation of patients with waldenström macroglobulinaemia: a task force from the 8th international workshop on waldenström macroglobulinaemia. Br J Haematol. 2016;175:77.
  • Banwait R, Aljawai Y, Cappuccio J, et al. Extramedullary Waldenström macroglobulinemia. Am J Hematol. 2015;90(2):100–104. doi:10.1002/ajh.23880
  • Castillo JJ, Treon SP. How we manage Bing-Neel syndrome. Br J Haematol. 2019;187(3):277–285. doi:10.1111/bjh.16167
  • Muñiz C, Martín-Martín L, López A, et al. Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome. Blood. 2014;123(12):1864–1869. doi:10.1182/blood-2013-11-537993
  • Gertz MA. Acute hyperviscosity: syndromes and management. Blood. 2018;132(13):1379–1385. doi:10.1182/blood-2018-06-846816
  • Gustine JN, Meid K, Dubeau T, et al. Serum IgM level as predictor of symptomatic hyperviscosity in patients with Waldenström macroglobulinaemia. Br J Haematol. 2017;177(5):717–725. doi:10.1111/bjh.14743
  • Muchtar E, Magen H, Gertz MA. How I treat cryoglobulinemia. Blood. 2017;129(3):289–298. doi:10.1182/blood-2016-09-719773
  • Saadoun D, Sellam J, Ghillani-Dalbin P, Crecel R, Piette JC, Cacoub P. Increased risks of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia. Arch Intern Med. 2006;166(19):2101–2108. doi:10.1001/archinte.166.19.2101
  • Berentsen S. New insights in the pathogenesis and therapy of cold agglutinin-mediated autoimmune hemolytic anemia. Front Immunol. 2020;11:590. doi:10.3389/fimmu.2020.00590
  • D’Sa S, Kersten MJ, Castillo JJ, et al. Investigation and management of IgM and Waldenström-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel. Br J Haematol. 2017;176(5):728–742. doi:10.1111/bjh.14492
  • Chaudhry HM, Mauermann ML, Rajkumar SV. Monoclonal gammopathy-associated peripheral neuropathy: diagnosis and management. Mayo Clin Proc. 2017;92(5):838–850. doi:10.1016/j.mayocp.2017.02.003
  • Le Cann M, Bouhour F, Viala K, et al. CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell-targeted therapies. Blood. 2020;136(21):2428–2436. doi:10.1182/blood.2020007092
  • Castillo JJ, Garcia-Sanz R, Hatjiharissi E, et al. Recommendations for the diagnosis and initial evaluation of patients with waldenström macroglobulinaemia: a task force from the 8th international workshop on waldenström macroglobulinaemia. Br J Haematol. 2016;175(1):77–86. doi:10.1111/bjh.14196
  • Sidana S, Larson DP, Greipp PT, et al. IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. Leukemia. 2020;34(5):1373–1382. doi:10.1038/s41375-019-0667-6
  • Milani P, Merlini G. Monoclonal IgM-related AL amyloidosis. Best Pract Res Clin Haematol. 2016;29(2):241–248. doi:10.1016/j.beha.2016.08.013
  • Sachchithanantham S, Roussel M, Palladini G, et al. European collaborative study defining clinical profile outcomes and novel prognostic criteria in monoclonal immunoglobulin m-related light chain amyloidosis. J Clin Oncol. 2016;34(17):2037–2045. doi:10.1200/JCO.2015.63.3123
  • Kastritis E, Leblond V, Dimopoulos MA, et al. Waldenström’s macroglobulinaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(5):860–862. doi:10.1093/annonc/mdy466
  • Andrade-Campos M, Murillo-Flórez I, García-Sanz R, Giraldo P. Immunoparesis in IgM gammopathies as a useful biomarker to predict disease progression. Clin Chem Lab Med. 2017;55(10):1598–1604. doi:10.1515/cclm-2016-0748
  • Leleu X, Moreau AS, Weller E, et al. Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. Leuk Lymphoma. 2008;49(6):1104–1107. doi:10.1080/10428190802074619
  • Itzykson R, Le Garff-tavernier M, Katsahian S, Diemert MC, Musset L, Leblond V. Serum-free light chain elevation is associated with a shorter time to treatment in Waldenstrom’s macroglobulinemia. Haematologica. 2008;93(5):793–794. doi:10.3324/haematol.12107
  • Xu L, Hunter ZR, Yang G, et al. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013;121(11):2051–2058. doi:10.1182/blood-2012-09-454355
  • Bagratuni T, Ntanasis-Stathopoulos I, Gavriatopoulou M, et al. Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies. Leukemia. 2018;32(12):2617–2625. doi:10.1038/s41375-018-0197-7
  • Drandi D, Genuardi E, Dogliotti I, et al. Highly sensitive mutation detection by droplet digital polymerase chain reaction in Waldenström macroglobulinemia. Haematologica. 2018;103(6):1029–1037. doi:10.3324/haematol.2017.186528
  • Lin P, Molina TJ, Cook JR, Swerdlow SH. Lymphoplasmacytic lymphoma and other non-marginal zone lymphomas with plasmacytic differentiation. Am J Clin Pathol. 2011;136(2):195–210. doi:10.1309/AJCP8FOIVTB6LBER
  • Paiva B, Montes MC, García-Sanz R, et al. Multiparameter flow cytometry for the identification of the Waldenström’s clone in IgM-MGUS and Waldenström’s Macroglobulinemia: new criteria for differential diagnosis and risk stratification. Leukemia. 2014;28(1):166–173. doi:10.1038/leu.2013.124
  • Jiménez C, Sebastián E, Chillón MC, et al. MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia. Leukemia. 2013;27(8):1722–1728. doi:10.1038/leu.2013.62
  • Hamadeh F, MacNamara SP, Aguilera NS, Swerdlow SH, Cook JR. MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma. Mod Pathol. 2015;28(4):564–574. doi:10.1038/modpathol.2014.120
  • Durot E, Kanagaratnam L, Zanwar S, et al. A prognostic index predicting survival in transformed Waldenström macroglobulinemia. Haematologica. 2020. doi:10.3324/haematol.2020.262899
  • Durot E, Tomowiak C, Michallet AS, et al. Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French innovative leukemia organization (FILO). Br J Haematol. 2017;179(3):439–448. doi:10.1111/bjh.14881
  • García-Sanz R, Jiménez C, Puig N, et al. Origin of Waldenstrom’s macroglobulinaemia. Best Pract Res Clin Haematol. 2016;29(2):136–147. doi:10.1016/j.beha.2016.08.024
  • Paiva B, Corchete LA, Vidriales MB, et al. The cellular origin and malignant transformation of Waldenström macroglobulinemia. Blood. 2015;125(15):2370–2380. doi:10.1182/blood-2014-09-602565
  • Morice WG, Chen D, Kurtin PJ, Hanson CA, McPhail ED. Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenström’s macroglobulinemia. Mod Pathol. 2009;22(6):807–816. doi:10.1038/modpathol.2009.34
  • Konoplev S, Medeiros LJ, Bueso-Ramos CE, Jorgensen JL, Lin P. Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Am J Clin Pathol. 2005;124(3):414–420. doi:10.1309/3G1XDX0DVHBNVKB4
  • San Miguel JF, Vidriales MB, Ocio E, et al. Immunophenotypic analysis of Waldenstrom’s macroglobulinemia. Semin Oncol. 2003;30(2):187–195. doi:10.1053/sonc.2003.50074
  • Ocio EM, Schop RF, Gonzalez B, et al. 6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis. Br J Haematol. 2007;136(1):80–86. doi:10.1111/j.1365-2141.2006.06389.x
  • Braggio E, Fonseca R. Genomic abnormalities of Waldenström macroglobulinemia and related low-grade B-cell lymphomas. Clin Lymphoma Myeloma Leuk. 2013;13(2):198–201. doi:10.1016/j.clml.2013.02.015
  • Schop RF, Fonseca R. Genetics and cytogenetics of Waldenstrom’s macroglobulinemia. Semin Oncol. 2003;30(2):142–145. doi:10.1053/sonc.2003.50075
  • García-Sanz R, Dogliotti I, Zaccaria GM, et al. 6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival. Br J Haematol. 2020;192:843.
  • Ocio EM, Hernandez JM, Mateo G, et al. Immunophenotypic and cytogenetic comparison of Waldenstrom’s macroglobulinemia with splenic marginal zone lymphoma. Clin Lymphoma. 2005;5(4):241–245. doi:10.3816/CLM.2005.n.007
  • Chang H, Samiee S, Li D, et al. Analysis of IgH translocations, chromosome 13q14 and 17p13.1(p53) deletions by fluorescence in situ hybridization in Waldenstrom’s macroglobulinemia: a single center study of 22 cases. Leukemia. 2004;18(6):1160–1162. doi:10.1038/sj.leu.2403369
  • Nguyen-Khac F, Lambert J, Chapiro E, et al. Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström’s macroglobulinemia. Haematologica. 2013;98(4):649–654. doi:10.3324/haematol.2012.070458
  • Treon SP, Xu L, Hunter Z. MYD88 Mutations and Response to Ibrutinib in Waldenström’s Macroglobulinemia. N Engl J Med. 2015;373(6):584–586. doi:10.1056/NEJMc1506192
  • Gracia-sanz R. WM, MYD88, and CXCR4: following the thread. J Am Society Hematol. 2016;128:746.
  • Hunter ZR, Xu L, Tsakmaklis N, et al. Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia. Blood Adv. 2018;2(21):2937–2946. doi:10.1182/bloodadvances.2018022962
  • Varettoni M, Arcaini L, Zibellini S, et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom’s macroglobulinemia and related lymphoid neoplasms. Blood. 2013;121(13):2522–2528. doi:10.1182/blood-2012-09-457101
  • Poulain S, Roumier C, Decambron A, et al. MYD88 L265P mutation in Waldenstrom macroglobulinemia. Blood. 2013;121(22):4504–4511. doi:10.1182/blood-2012-06-436329
  • Treon SP, Xu L, Guerrera ML, et al. Genomic landscape of waldenström macroglobulinemia and its impact on treatment strategies. J Clin Oncol. 2020;38(11):1198–1208. doi:10.1200/JCO.19.02314
  • Jiménez C, Chillón M, Balanzategui A, et al. Detection of MYD88 L265P mutation by real-time allele-specific oligonucleotide polymerase chain reaction. Appl Immunohistochem Mol Morphol. 2014;22(10):768–773. doi:10.1097/PAI.0000000000000020
  • Schmidt J, Federmann B, Schindler N, et al. MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity. Br J Haematol. 2015;169(6):795–803. doi:10.1111/bjh.13361
  • Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res. 2010;16(11):2927–2931. doi:10.1158/1078-0432.CCR-09-2329
  • Kaiser LM, Hunter ZR, Treon SP, Buske C. CXCR4 in Waldenström’s Macroglobulinema: chances and challenges. Leukemia. 2021;35(2):333–345. doi:10.1038/s41375-020-01102-3
  • Hunter ZR, Yang G, Xu L, Liu X, Castillo JJ, Treon SP. Genomics, signaling, and treatment of waldenström macroglobulinemia. J Clin Oncol. 2017;35(9):994–1001. doi:10.1200/JCO.2016.71.0814
  • Varettoni M, Boveri E, Zibellini S, et al. Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: a multicentric study of the Rete Ematologica Lombarda (REL) network. Am J Hematol. 2019;94(11):1193–1199. doi:10.1002/ajh.25600
  • Jiménez C, Prieto-Conde MI, García-álvarez M, et al. Unraveling the heterogeneity of IgM monoclonal gammopathies: a gene mutational and gene expression study. Ann Hematol. 2018;97(3):475–484.
  • Poulain S, Roumier C, Venet-Caillault A, et al. Genomic landscape of CXCR4 mutations in waldenström macroglobulinemia. Clin Cancer Res. 2016;22(6):1480–1488. doi:10.1158/1078-0432.CCR-15-0646
  • Jiménez C, Alonso-álvarez S, Alcoceba M, et al. From Waldenström’s macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation. Blood Cancer J. 2017;7(8):e591. doi:10.1038/bcj.2017.72
  • Bustoros M, Sklavenitis-Pistofidis R, Kapoor P, et al. Progression risk stratification of asymptomatic waldenström macroglobulinemia. J Clin Oncol. 2019;37(16):1403–1411. doi:10.1200/JCO.19.00394
  • Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009;113(18):4163–4170. doi:10.1182/blood-2008-08-174961
  • Castillo JJ, Advani RH, Branagan AR, et al. Consensus treatment recommendations from the tenth international workshop for waldenström macroglobulinaemia. Lancet Haematol. 2020;7(11):e827–e837. doi:10.1016/S2352-3026(20)30224-6